Vanna Health raises $17M Series A to expand evidence-based care for serious mental illness
What's the deal? Vanna Health, a San Francisco value-based health technology company, has closed a $17 million Series A round.
AlleyCorpDealroom has a profile for this one. Try Dealroom → and a national insurer co-led the round, with Health Velocity CapitalDealroom has a profile for this one. Try Dealroom → participating.
The company supports people living with serious mental illness through community-based coaching, blending clinical care with proprietary technology.
Why now? Serious mental illness — including schizophrenia, schizoaffective disorder, and bipolar disorder — affects roughly 14 million Americans.
Yet a wide gap persists between care proven to work and what patients actually receive. Vanna built its model to close it.
The funding will expand its clinical reach, deepen its technology, and grow its teams. Vanna currently operates in four states and plans to enter new markets.
What could go wrong? Scaling a high-touch, human-centred care model is hard. Vanna must grow into new states without sacrificing quality or the personal connection at its core.
It also depends on partnerships with insurers and community organisations to deliver coordinated care and control costs.
The signal: The round reflects how value-based health technology investors are increasingly chasing the costliest, most complex corners of healthcare, with serious mental illness affecting roughly 14 million Americans. Backing from both AlleyCorp and a national insurer signals confidence in Vanna's breakout-stage model and its ability to scale across new states without losing the human touch at its core.
Read more: M2 PressWIRE
